Latest Pharma Insights
Aeon Gains FDA Clarity On Botox Biosimilar Path
FDA feedback following a January type 2a meeting supports Aeon’s analytical strategy for its Botox biosimilar, providing a clearer roadmap to complete comparability work in 2026 and shaping the next phase of regulatory engagement.
Generics Bulletin - March 26, 2026
FDA feedback following a January type 2a meeting supports Aeon’s analytical strategy for its Botox biosimilar, providing a clearer roadmap to complete comparability work in 2026 and shaping the next phase of regulatory engagement.
Generics Bulletin - March 26, 2026
Yoshindo Builds In-House Biosimilars Capacity With Cytiva Support
Cytiva’s FlexFactory deal with Yoshindo will establish domestic biosimilar manufacturing in Japan by 2028, as the firm pivots from JV-led development toward in-house production amid growing demand and policy support for lower-cost biologics.
Generics Bulletin - March 26, 2026
Cytiva’s FlexFactory deal with Yoshindo will establish domestic biosimilar manufacturing in Japan by 2028, as the firm pivots from JV-led development toward in-house production amid growing demand and policy support for lower-cost biologics.
Generics Bulletin - March 26, 2026
Executives On The Move: Alphamab Oncology Gets A New CFO From AstraZeneca
Recent moves in the industry include changes at the top at Mestag Therapeutics, Atossa Therapeutics and Kaida BioPharma, plus Alchemab Therapeutics gets a new CBO from Sanofi.
Scrip - March 26, 2026
Recent moves in the industry include changes at the top at Mestag Therapeutics, Atossa Therapeutics and Kaida BioPharma, plus Alchemab Therapeutics gets a new CBO from Sanofi.
Scrip - March 26, 2026
NHS Staff Lack Basic Training For EPRs: Report
Adoption of electronic patient records is high in the NHS, but staff often struggle to use them effectively, according to a survey from the Health Foundation.
Medtech Insight - March 26, 2026
Adoption of electronic patient records is high in the NHS, but staff often struggle to use them effectively, according to a survey from the Health Foundation.
Medtech Insight - March 26, 2026
Midterm Swiss-EU Medtech MRA Still On Track After Bilaterals III
Renewal of the Swiss-EU Mutual Recognition Agreement for medical devices may still be a year or two away, but momentum towards ratification was maintained in March when Swiss and EU political leaders signed the final outstanding agreements of the Bilaterals III sectoral agreements.
Medtech Insight - March 26, 2026
Renewal of the Swiss-EU Mutual Recognition Agreement for medical devices may still be a year or two away, but momentum towards ratification was maintained in March when Swiss and EU political leaders signed the final outstanding agreements of the Bilaterals III sectoral agreements.
Medtech Insight - March 26, 2026
Biogen Added To Alteogen’s Long List Of Partners
Following a deal with Tesaro in January, Alteogen inks another global out-licensing agreement for its subcutaneous delivery enabling platform technology, this time with Biogen.
Scrip - March 26, 2026
Following a deal with Tesaro in January, Alteogen inks another global out-licensing agreement for its subcutaneous delivery enabling platform technology, this time with Biogen.
Scrip - March 26, 2026
Thorne’s Picture Of Dietary Supplement Personalization: ‘Meet Them On Their Journey’
“What they want when they think about personalization, is that you meet them on their journey, where they are on their terms. That's what personalization is. How do brands do that? You can't do that by just broadcasting an ad,” CEO Colin Watts says.
HBW Insight - March 26, 2026
“What they want when they think about personalization, is that you meet them on their journey, where they are on their terms. That's what personalization is. How do brands do that? You can't do that by just broadcasting an ad,” CEO Colin Watts says.
HBW Insight - March 26, 2026
Executives On The Move: Alphamab Oncology Gets A New CFO From AstraZeneca
Recent moves in the industry include changes at the top at Mestag Therapeutics, Atossa Therapeutics and Kaida BioPharma, plus Alchemab Therapeutics gets a new CBO from Sanofi.
Scrip - March 26, 2026
Recent moves in the industry include changes at the top at Mestag Therapeutics, Atossa Therapeutics and Kaida BioPharma, plus Alchemab Therapeutics gets a new CBO from Sanofi.
Scrip - March 26, 2026
Biogen Added To Alteogen’s Long List Of Partners
Following a deal with Tesaro in January, Alteogen inks another global out-licensing agreement for its subcutaneous delivery enabling platform technology, this time with Biogen.
Scrip - March 26, 2026
Following a deal with Tesaro in January, Alteogen inks another global out-licensing agreement for its subcutaneous delivery enabling platform technology, this time with Biogen.
Scrip - March 26, 2026
NHS Staff Lack Basic Training For EPRs: Report
Adoption of electronic patient records is high in the NHS, but staff often struggle to use them effectively, according to a survey from the Health Foundation.
Medtech Insight - March 26, 2026
Adoption of electronic patient records is high in the NHS, but staff often struggle to use them effectively, according to a survey from the Health Foundation.
Medtech Insight - March 26, 2026
Midterm Swiss-EU Medtech MRA Still On Track After Bilaterals III
Renewal of the Swiss-EU Mutual Recognition Agreement for medical devices may still be a year or two away, but momentum towards ratification was maintained in March when Swiss and EU political leaders signed the final outstanding agreements of the Bilaterals III sectoral agreements.
Medtech Insight - March 26, 2026
Renewal of the Swiss-EU Mutual Recognition Agreement for medical devices may still be a year or two away, but momentum towards ratification was maintained in March when Swiss and EU political leaders signed the final outstanding agreements of the Bilaterals III sectoral agreements.
Medtech Insight - March 26, 2026
Thorne’s Picture Of Dietary Supplement Personalization: ‘Meet Them On Their Journey’
“What they want when they think about personalization, is that you meet them on their journey, where they are on their terms. That's what personalization is. How do brands do that? You can't do that by just broadcasting an ad,” CEO Colin Watts says.
HBW Insight - March 26, 2026
“What they want when they think about personalization, is that you meet them on their journey, where they are on their terms. That's what personalization is. How do brands do that? You can't do that by just broadcasting an ad,” CEO Colin Watts says.
HBW Insight - March 26, 2026
Aeon Gains FDA Clarity On Botox Biosimilar Path
FDA feedback following a January type 2a meeting supports Aeon’s analytical strategy for its Botox biosimilar, providing a clearer roadmap to complete comparability work in 2026 and shaping the next phase of regulatory engagement.
Generics Bulletin - March 26, 2026
FDA feedback following a January type 2a meeting supports Aeon’s analytical strategy for its Botox biosimilar, providing a clearer roadmap to complete comparability work in 2026 and shaping the next phase of regulatory engagement.
Generics Bulletin - March 26, 2026
Yoshindo Builds In-House Biosimilars Capacity With Cytiva Support
Cytiva’s FlexFactory deal with Yoshindo will establish domestic biosimilar manufacturing in Japan by 2028, as the firm pivots from JV-led development toward in-house production amid growing demand and policy support for lower-cost biologics.
Generics Bulletin - March 26, 2026
Cytiva’s FlexFactory deal with Yoshindo will establish domestic biosimilar manufacturing in Japan by 2028, as the firm pivots from JV-led development toward in-house production amid growing demand and policy support for lower-cost biologics.
Generics Bulletin - March 26, 2026
Daiichi Sankyo Looks To Deploy ‘Smarter’ R&D Approach To ADCs
As a pioneer in antibody-drug conjugates, Daiichi Sankyo has seen both breakthroughs and setbacks in advancing the modality. CEO Ken Keller told In Vivo the company had turned to next generation biomarker technologies to navigate these challenges and sharpen its R&D strategy.
In Vivo - March 25, 2026
As a pioneer in antibody-drug conjugates, Daiichi Sankyo has seen both breakthroughs and setbacks in advancing the modality. CEO Ken Keller told In Vivo the company had turned to next generation biomarker technologies to navigate these challenges and sharpen its R&D strategy.
In Vivo - March 25, 2026
Could CAR-T Cells Cure Some Autoimmune Diseases?
Clinical evidence points to immune system ‘reset’ and durable remission. Investors have taken note and the deals have followed.
In Vivo - March 25, 2026
Clinical evidence points to immune system ‘reset’ and durable remission. Investors have taken note and the deals have followed.
In Vivo - March 25, 2026
The Commercial Test: Psychedelics Move From Fringe Science To Doctor’s Office
Compass Pathways, now leading the race toward regulatory approval for a classic psychedelic, mapped out its strategy behind what could become one of the industry’s more unconventional drug launches.
In Vivo - March 25, 2026
Compass Pathways, now leading the race toward regulatory approval for a classic psychedelic, mapped out its strategy behind what could become one of the industry’s more unconventional drug launches.
In Vivo - March 25, 2026